Impact News +++ USA Rare Earth Shares Spike More Than 18% On News Of Talks With Trump Administration (ZeroHedge) +++ MP MATERIALS Aktie -3,21%

ARMATA Aktie

>ARMATA Performance

1 Woche: -1,6%

1 Monat: +23,9%

3 Monate: +48,8%

6 Monate: +70,6%

1 Jahr: +22,0%

laufendes Jahr: +27,1%

>ARMATA Aktie

Name:

ARMATA PHARMACEUT.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US04216R1023 / A2PKLC

Symbol/ Ticker:

TG1N (Frankfurt)

Kürzel:

FRA:TG1N, ETR:TG1N, TG1N:GR

Index:

Webseite:

https://www.armatapharma...

Profil:

Armata Pharmaceuticals Inc. is a biotechnology com..
>Volltext..

Marktkapitalisierung:

91.19 Mio. EUR

Unternehmenswert:

209.46 Mio. EUR

Umsatz:

5.84 Mio. EUR

EBITDA:

-28.84 Mio. EUR

Nettogewinn:

-21.87 Mio. EUR

Gewinn je Aktie:

-0.6 EUR

Schulden:

122.45 Mio. EUR

Liquide Mittel:

3.68 Mio. EUR

Operativer Cashflow:

-26.86 Mio. EUR

Bargeldquote:

0.04

Umsatzwachstum:

67.92%

Gewinnwachstum:

65.13%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ARMATA

Letzte Datenerhebung:

03.10.25

>ARMATA Kennzahlen

Aktien/ Unternehmen:

Aktien: 36.23 Mio. St.

Frei handelbar: 29.84%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 60

Umsatz/Mitarb.: 0.07 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 220.76%

Bewertung:

KGV: -

KGV lG: -

KUV: 15.21

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 79.28%

Gewinnmarge: -374.3%

Operative Marge: -514.41%

Managementeffizenz:

Gesamtkaprendite: -27.19%

Eigenkaprendite: -

>ARMATA Peer Group

Es sind 599 Aktien bekannt.

>ARMATA Chart & Kurs - Stuttgart

>ARMATA News

08.09.25 - 13:01	Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology (PR Newswire)
	Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES, Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company......

04.09.25 - 13:03	Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
	LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

15.08.25 - 19:45	All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy (Zacks)
	Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

13.08.25 - 05:00	Armata Posts 59 Percent Q2 Revenue Jump (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.25 - 01:00	Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
	Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.08.25 - 22:06	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update (PR Newswire)
	Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"),......

21.05.25 - 17:30	ARMP Soars 72% in a Month Following Infectious Disease Study Success (Zacks)
	Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease....

19.05.25 - 13:01	Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia (PR Newswire)
	All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes and prevented relapse compared to best available antibiotic therapy No treatment-related serious adverse events were observed......

15.05.25 - 01:00	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
	Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 47.37% and 64.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

14.05.25 - 22:09	Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update (PR Newswire)
	LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

01.05.25 - 13:06	Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 (PR Newswire)
	Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia Topline data anticipated in Q2 2025 to support potential future pivotal bacteremia efficacy trial LOS ANGELES, May 1, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc.......

21.03.25 - 06:18	Armata Pharmaceuticals GAAP EPS of -$0.23, revenue of $1.2M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.03.25 - 23:00	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update (PR Newswire)
	LOS ANGELES, March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of......

12.03.25 - 22:18	Armata Pharmaceuticals announces $10M secured credit agreement with Innoviva (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.03.25 - 22:12	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
	Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES, March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of......

11.03.25 - 12:03	Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit (PR Newswire)
	LOS ANGELES, March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of......

14.11.24 - 00:48	Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
	Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 46.43% and 230.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?...

14.11.24 - 00:06	Armata Pharmaceuticals GAAP EPS of -$0.15 beats by $0.13 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.24 - 22:07	Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update (PR Newswire)
	LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections,......

12.09.24 - 19:33	Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
	Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer heilt, hat recht. - Hippokrates

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram